A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive^TM) for COVID-19 Patients

Table 4

Secondary clinical outcomes.

Parameter	Active		Placebo		value
	Number of patients	Percentage	Number of patients	Percentage
Ordinal scale
0	19	44.22	11	23.40	0.03
1	26	57.78	18	38.30
2	0	0	16	34.04
3	0	0	1	2.13
4	0	0	1	2.13
Number of days in hospital
Less than 6	1	2.22	0		NS
6–10	44	97.78	42	89.36
>10	0		5	10.64
No. of days of RT-PCR negative
6 days	29	64.44	27	57.45	NS
7–10	1	2.22	7	14.89
10–14	15	33.33	11	23.40
>14	0	0.00	2	4.26

Patients with ordinal scale of “0”: no clinical evidence of infection. NS: not significant.